Aura Biosciences Statistics
Total Valuation
AURA has a market cap or net worth of $446.83 million. The enterprise value is $314.19 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AURA has 64.20 million shares outstanding. The number of shares has increased by 21.53% in one year.
| Current Share Class | 64.20M |
| Shares Outstanding | 64.20M |
| Shares Change (YoY) | +21.53% |
| Shares Change (QoQ) | +1.76% |
| Owned by Insiders (%) | 1.80% |
| Owned by Institutions (%) | 44.29% |
| Float | 37.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.23 |
| P/TBV Ratio | 3.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.15, with a Debt / Equity ratio of 0.13.
| Current Ratio | 8.15 |
| Quick Ratio | 7.85 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -73.52% and return on invested capital (ROIC) is -43.38%.
| Return on Equity (ROE) | -73.52% |
| Return on Assets (ROA) | -40.06% |
| Return on Invested Capital (ROIC) | -43.38% |
| Return on Capital Employed (ROCE) | -74.67% |
| Weighted Average Cost of Capital (WACC) | 5.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$939,743 |
| Employee Count | 113 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AURA has paid $108,000 in taxes.
| Income Tax | 108,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.37% in the last 52 weeks. The beta is 0.35, so AURA's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +29.37% |
| 50-Day Moving Average | 6.40 |
| 200-Day Moving Average | 6.15 |
| Relative Strength Index (RSI) | 53.14 |
| Average Volume (20 Days) | 312,025 |
Short Selling Information
The latest short interest is 2.01 million, so 3.14% of the outstanding shares have been sold short.
| Short Interest | 2.01M |
| Short Previous Month | 2.62M |
| Short % of Shares Out | 3.14% |
| Short % of Float | 5.42% |
| Short Ratio (days to cover) | 6.43 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -112.79M |
| Pretax Income | -106.08M |
| Net Income | -106.19M |
| EBITDA | -111.66M |
| EBIT | -112.79M |
| Earnings Per Share (EPS) | -$1.76 |
Full Income StatementBalance Sheet
The company has $144.24 million in cash and $17.38 million in debt, giving a net cash position of $126.86 million or $1.98 per share.
| Cash & Cash Equivalents | 144.24M |
| Total Debt | 17.38M |
| Net Cash | 126.86M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 136.91M |
| Book Value Per Share | 2.15 |
| Working Capital | 131.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$84.74 million and capital expenditures -$447,000, giving a free cash flow of -$85.19 million.
| Operating Cash Flow | -84.74M |
| Capital Expenditures | -447,000 |
| Depreciation & Amortization | 1.13M |
| Net Borrowing | n/a |
| Free Cash Flow | -85.19M |
| FCF Per Share | -$1.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |